ERBB2 and breast carcinoma: Separately, interleukin-33R, otherwise known as suppression of tumorigenicity 2 protein/interleukin-33R (ST2/IL33-R), has been assessed in small numbers as another novel biomarker in 22 patients who receive trastuzumab, pertuzumab, and docetaxel for HER2 breast cancer [90].